Fig. 7
From: Emerging strategies to overcome resistance to third-generation EGFR inhibitors
Chemical structures and structure–activity relationships of dual-site inhibitors. A Structure-guided design and synthesis of mutant-selective lead compounds and their inhibitory activities against EGFR. B Structural superposition of the ATP site binding inhibitor LN2057 (PDB code: 6V6K) and the allosteric inhibitor EAI045 (PDB code: 6P1L); C X-ray cocrystal structure of EGFR T790M/V948R with compound 34 (PDB code: 6WA2); D X-ray cocrystal structure of EGFR T790M/V948R with compound 36 (PDB code: 6WXN)